CAR-T cells are developed by redesigning the T cells to actively find and destroy a specific part of cancer cells by inserting a chimeric antigen receptor(CAR) gene. This allows CAR-T cells to destroy the cancer cell while effectively, minimizing damage of normal cells.​

Conventional CAR-T has limitation in treating solid cancers. Cartexell developed a proprietary new CAR-T 2.0 technology, which controlls CAR-T cells and reinforce its anti-cancer activity. CAR-T 2.0 technology expresses a functional gene to block immune checkpoints, enhance infiltration of T cell, increase recruitment of immune cells or improve survival of T cell as well as CAR gene in T-cells concomitantly. ​

Cartexell possesses multiple CAR-T cell therapy candidates targeting solid tumors. ‘CX801’, the first product developed by Cartexell's research team, (currently owned by Helixmith) targets colorectal, ovarian, and prostate cancer, and ‘CX804’ targets neuroblastoma, ovarian and lung cancer. Cartexell is also developing CAR-T cell therapies targeting a diverse set of solid tumor antigens such as CX803 and CX805.​